GLUE
Monte Rosa Therapeutics Inc
11.70$
-1.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 100.0% | 100.0% | |
| – | – | – | – | – | 10.7% | 6.8% | |
| – | – | – | – | – | 89.3% | 93.2% | |
| – | – | – | – | – | 160.8% | 114.4% | |
| – | – | – | – | – | 46.5% | 29.4% | |
| – | – | – | – | – | 196.5% | 137.1% | |
| – | – | – | – | – | -107.3% | -43.8% | |
| – | – | – | – | – | -92.7% | -32.1% | |
| – | – | – | – | – | 3.4% | -0.9% | |
| – | – | – | – | – | -96.1% | -31.2% | |
| – | – | – | – | – | -82.0% | -25.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.